AstraZeneca signs agreement to mass-produce Oxford Uni non-profit coronavirus vaccine – to help millions around the world – The Sun

0
116


A CORONAVIRUS vaccine that could save millions of lives could be ready in a few months as part of a historic agreement.

British pharmaceutical company AstraZeneca will manufacture and distribute the potential of the University of Oxford’s COVID-19 vaccine on a “worldwide basis” on a “virtually free basis”, if trials at Oxford are deemed successful.

⚠️ Read our coronavirus live blog for the latest news and updates

    Oxford University vaccine gave monkey immunity to coronavirus
University of Oxford vaccine gives monkey immunity to coronavirusCredits: Getty Images – Getty

The Cambridge-based company has not specified when it will start producing the vaccine for Covid-19, which has so far infected more than 3 million people and killed more than 215,000 people.

Although there are more than 70 vaccines under development for the coronavirus, industry experts expect development to take at least 12 to 18 months.

Professor Sir John Bell, Regius Professor of Medicine at the University of Oxford, said today that the new vaccination would be “distributed at cost” and would be “essentially free” during the initial deployment, which will focus on the most vulnerable in society.

Despite the enthusiasm for vaccination, he said it was important for people to understand that it was still a development program and that the team still had to demonstrate that it would work on a population human.

“TThe Oxford team led by Andy Pollard at the clinic has done a great job, they have vaccinated several hundred people now and we hope to have a signal as to whether or not it works by the end of June.

“The challenge is that once we get regulatory approval, we don’t want to have to go back to the beginning and figure out how to make it on a large scale.”

    Microbiologist Elisa Granato, 32, receives injection from UK human trials for coronavirus vaccine as Oxford University coronavirus vaccine trial begins2
Microbiologist Elisa Granato, 32, receives injection in UK human trials for coronavirus vaccine as Oxford University coronavirus vaccine trial beginsCredit: PA: Press Association

Speaking this morning about the Today program, the professor said the British manufacturing capacity was “not where it should be”, and added that AstraZeneca would be able to “significantly improve this”.

He added: ” It’s really about preparing the facilities to expand the vaccine, so we will have to do 30 or 40 million doses at first to try to get enough so that if approved, we can vaccinate people immediately.

“For example things like the vials in which you put the vaccine in the so-called filling and finishing, there are only 200 million vials left in the world because they have been aspirated by various people who can anticipate the ‘Arrival of a vaccine, so there are many challenges for it to work and we are delighted to have such a great and powerful partner with us.’

The professor said the first part of the plan was to make sure there were enough vaccinations ashore for the vulnerable.

“These are 30 million doses of vaccine, which should cover all vulnerable patients, but at the same time we are going to start talking and indeed Oxford has already started talking to some overseas partners so that they can get themselves to prepare. “

Pascal Soriot, CEO of AstraZeneca, said in a statement: “We hope that by joining forces, we can accelerate the globalization of a vaccine to fight the virus and protect people from the deadliest pandemic in the world.” ‘a generation’.

Speaking also on the Today program, he admitted that it was a financial risk for the company, but said that “the time had come to take these risks” and that solutions were needed to manage the pandemic.

He said the company would rely on manufacturing organizations and increase its own manufacturing capacity in the coming months so that it could distribute the vaccine “if it works.”

Science is uncertain, and no vaccine can work, but this agreement gives the UK the best chance we can of a breakthrough that could defeat this terrible virus.

Matt Hancock

Soriot added that there are already collaborations between the Oxford unit and partners around the world.

“I hope it will not be the only vaccine available, I hope that several will be available to meet the different needs of businesses around the world.”

He confirmed that the vaccine would be produced at cost during the pandemic period. He said the cost of the vaccine would not be very high and would be available to everyone.

The Jenner Institute and Oxford Vaccine Group have been working on a vaccine, called ChAdOx1 nCoV-19, with work to start on millions of doses before trials show it works.

The team last week tested the first volunteers in a vaccine trial, with early readings possible in May.

Health Secretary Matt Hancock called AstraZenca’s decision “very good news.”

He tweeted, “The Oxford vaccine is one of the most advanced in the world.

“Bringing together the best British science and the best of British business will give us the best possible shot at a vaccine.”

“Science is uncertain, and no vaccine can work, but this agreement gives the UK the best chance we can of a breakthrough that could defeat this terrible virus.

“I send my best wishes to everyone involved – for the good of the nation and the world. “

While some experts say the vaccine will be ready in 12 to 18 months, others have said it is an “optimistic figure”.

James Cutrell, director of the infectious disease fellowship program at the University of Texas Southwestern Medical Center in Dallas, said the figure would only be based on the assumption that all trials would go as planned.

How is a vaccine approved?

For a vaccination to be made available to the general public, it must go through a long process. Scientists working on a coronavirus vaccine are trying to speed up this process.

Here are the main steps:

  • The exploratory phase – is the research phase, used to discover what can help treat or prevent a disease
  • Preclinical stage – laboratory and animal research
  • Clinical development – this is a three-step process. In stage one, small groups receive the vaccine, in stage two it is given to people with characteristics similar to those for whom the vaccine is intended and the third step is to deploy the vaccine to thousands of people to test it
  • Regulatory review and approval – where the right bodies are contacted and in touch with bringing it to market
  • Manufacturing – production of the drug
  • Quality control – does the vaccine do what it plans

Speaking to The Huffington Post, he said, “I would say that the 12 to 18 months that some experts have echoed are realistic, but optimistic.

“It is based on the assumption that each phase of the trials is going as planned, with an optimistic timetable for each of these stages. “

As the new vaccine continues through the development phase, a drug used to treat Ebola patients has shown “very promising” early results in a trial of people hospitalized for coronavirus, scientists say.

Patients who received remdesivir had a recovery time that was almost a third faster than those who received placebo, the first results of an international clinical trial showed.
Abdel Babiker, professor of epidemiology and medical statistics at UCL, told the BBC Radio 4 Today program: “These are very encouraging results from the first large-scale randomized trial to report on any treatment for Covid- 19. “

2

A second glimmer of hope: Could the Ebola drug help Covid-19 patients recover faster?

A drug used to treat Ebola patients has shown “very promising” early results in a trial of people admitted to hospital with a coronavirus, scientists say.

Patients who received remdesivir had a recovery time that was almost a third faster than those who received placebo, the first results of an international clinical trial showed.

Abdel Babiker, professor of epidemiology and medical statistics at UCL, told the BBC Radio 4 Today program: “These are very encouraging results from the first large-scale randomized trial to report on any treatment for Covid- 19. “

He said the group of adults admitted to hospital with an advanced coronavirus who received remdesivir recovered “much faster” than the group who received a placebo.

Preliminary results also suggest a survival benefit, with an 8% lower mortality rate for the group receiving the drug, compared to 11.6% for the placebo group, said the National Institute of Allergies and Infectious Diseases ( NIAD).

More than 1,000 patients have been recruited worldwide, including 46 from the UK, for the Covid-19 adaptive therapy trial, which began in early April. The scientists involved in the study defined recovery as a patient who was healthy enough to get oxygen, get out of the hospital, or even return to normal activity levels.

During the trial, which involved more than 70 hospitals around the world, patients received the antiviral drug daily for 10 days while in the hospital. Professor Mahesh Parmar, director of the clinical research unit of the Medical Research Council at UCL, who supervised the European part of the trial, said that scientists will continue to collect new data while the first results are reviewed by regulators.

Professor Parmar said: “These results are indeed very promising. They show that this drug can clearly improve recovery time.

“Before this drug is no longer widely available, a number of things must happen: the data and the results must be reviewed by the regulatory authorities to assess whether the drug can be authorized and then they must be evaluated by the authorities competent sanitary facilities in various countries. countries.

“While this is happening, we will get longer-term data from this trial, and others, to find out if the drug also prevents deaths from Covid-19. “

He said the group of adults admitted to hospital with an advanced coronavirus who received remdesivir recovered “much faster” than the group who received a placebo.
Preliminary results also suggest a survival benefit, with an 8% lower mortality rate for the group receiving the drug, compared to 11.6% for the placebo group, said the National Institute of Allergies and Infectious Diseases ( NIAD).
More than 1,000 patients have been recruited worldwide, including 46 from the UK, for the Covid-19 adaptive therapy trial, which began in early April.
The scientists involved in the study defined recovery as a patient who was healthy enough to get oxygen, get out of the hospital, or even return to normal activity levels.
During the trial, which involved more than 70 hospitals around the world, patients received the antiviral drug daily for 10 days while in the hospital.
Professor Mahesh Parmar, director of the clinical research unit of the Medical Research Council at UCL, who supervised the European part of the trial, said that scientists will continue to collect new data while the first results are reviewed by regulators.
Professor Parmar said: “These results are indeed very promising. They show that this drug can clearly improve recovery time.
“Before this drug is no longer widely available, a number of things must happen: the data and the results must be reviewed by the regulatory authorities to assess whether the drug can be authorized and then they must be evaluated by the authorities competent sanitary facilities in various countries. countries.
“While this is happening, we will get longer-term data from this trial, and others, to find out if the drug also prevents deaths from Covid-19. “


We pay for your stories! Do you have a story for the Sun Online news team? Write to us at [email protected] or call 0207 782 4368. You can WhatsApp to us on 07810 791 502. We also pay for videos. Click here to download yours.



LEAVE A REPLY

Please enter your comment!
Please enter your name here